Esperion Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $80,104 | $168,446 | $87,309 | $82,385 |
Gross Profit | 45,531 | 140,592 | 31,889 | 53,842 |
EBITDA | -6,581 | 85,233 | -9,256 | 7,788 |
EBIT | -6,608 | 85,207 | -9,282 | 7,761 |
Net Income | -25,196 | 61,831 | -31,333 | -12,725 |
Net Change In Cash | 80,104 | 168,446 | 87,309 | 82,385 |
Free Cash Flow | -27,911 | 45,432 | -4,286 | -31,422 |
Cash | 156,158 | 167,852 | 92,447 | 86,061 |
Basic Shares | 251,353 | 284,573 | 198,153 | 196,841 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $403,135 | $332,314 | $116,334 | $75,475 |
Gross Profit | 273,911 | 263,713 | 73,067 | 48,508 |
EBITDA | 60,273 | 7,569 | -150,108 | -176,349 |
EBIT | 60,168 | 7,506 | -150,272 | -176,849 |
Net Income | -22,682 | -51,745 | -209,248 | -233,659 |
Net Change In Cash | 403,135 | 332,314 | 116,334 | 75,475 |
Cost of Revenue | -134,117 | |||
Free Cash Flow | -13,093 | -23,971 | -135,487 | -174,827 |
Cash | 167,852 | 144,761 | 82,248 | 124,775 |
Basic Shares | 207,865 | 187,181 | 103,106 | 66,407 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.10 |
2025-12-31 | $0.22 |
2025-09-30 | -$0.16 |
2025-06-30 | -$0.02 |